1. Steinberg DH, Mishra S, Javaid A, et al. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (> or = 3.5 mm) coronary arteries. Am J Cardiol 2007;99:599–602.
2. Quizhpe AR, Feres F, de Ribamar Costa J Jr, et al. Drug-eluting stents vs bare metal stents for the treatment of large coronary vessels. Am Heart J 2007;154:373–378.
3. Joen DJ, Hong GR, Bae JH, et al. Immediate and follow-up results after long stent implantaton in diffuse long coronary lesions. Korean J Med 2000;58:48–57.
4. James SK, Stenestrand U, Lindbäck J, et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 2009;360:1933–1945.
5. Kishore JH, Ricardo C, Pichard L. Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials: finding from the GHOST Study (Guthrie Health System Off-Label StenT Study). J Interv Cardiol 2008;21:315–324.
6. Koutouzis M, Nikolidakis S, Arealis G, Kyriakides ZS. Very late in-stent restenosis in a bare metal stent. Cardiology 2007;107:360–361.
8. Strozzi M, Anić D. Comparison of stent graft, sirolimus stent, and bare metal stent implanted in patients with acute coronary syndrome: clinical and angiographic follow-up. Croat Med J 2007;48:348–352.
9. Khattab AA, Otto A, Hochadel M, Toelg R, Geist V, Richardt G. Drug-eluting stents versus bare metal stents following rotational atherectomy for heavily calcified coronary lesions: late angiographic and clinical follow-up results. J Interv Cardiol 2007;20:100–106.
10. Jensen J, Lagerqvist B, Aasa M, Särev T, Nilsson T, Tornvall P. Clinical and angiographic follow-up after coronary drug-eluting and bare metal stent implantation: do drug-eluting stents hold the promise? J Intern Med 2006;260:118–124.
11. Steinberg DH, Waksman R. Drug-eluting stent thrombosis vs bare metal stent restenosis: finding the lesser of two evils. Am Heart Hosp J 2007;5:151–154.
12. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989–997.
13. Fuchs AT, Kuehnl A, Pelisek J, et al. Meta-analysis shows similar risk of thrombosis after drug-eluting stent, bare-metal stent, or angioplasty. Endothelium 2008;15:93–100.
14. Lee SH, Jeong MH, Hong YJ, et al. A long stent is the only predictive factor for coronary stent restenosis. Korean J Med 2001;60:529–536.
15. Barlis P, Kaplan S, Dimopoulos K, Ferrante G, Di Mario C. Comparison of bare-metal and sirolimus-or paclitaxel-eluting stents for aorto-ostial coronary disease. Cardiology 2008;111:270–276.
16. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215–1223.
17. Tanigawa J, Sutaria N, Goktekin O, Di Mario C. Treatment of unprotected left main coronary artery stenosis in the drug-eluting stent era. J Interv Cardiol 2005;18:455–465.
18. Tanzilli G, Pelliccia F, Pasceri V, et al. Randomized study on provisional stenting with sirolimus-eluting stent vs. bare metal stent for the treatment of true coronary bifurcations: the PROSUMER (PROvisional with sirolimus-eluting vs. bare metal stents in truE bifuRcations) study. Int J Cardiol 2011;146:240–241.
19. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297:1992–2000.
21. Zimarino M, Renda G, De Caterina R. Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents. Drugs 2005;65:725–732.
22. Moohebati M, Falsoleiman H, Dehghani M, et al. Serum inflammatory and immune marker response after bare-metal or drug-eluting stent implantation following percutaneous coronary intervention. Angiology 2011;62:184–190.
23. Alt E, Haehnel I, Beilharz C, et al. Inhibition of neointimaformation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation 2000;101:1453–1458.
24. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532–539.
25. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020–1029.
26. Chechi T, Vittori G, Biondi Zoccai GG, et al. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 2007;20:282–291.
27. De Felice F, Fiorilli R, Parma A, et al. Comparison of one-year cardiac events with drug-eluting versus bare metal stent implantation in rescue coronary angioplasty. Am J Cardiol 2011;107:210–214.
28. Seo YU, Koh YY, Kang MJ, Chang KS, Hong SP. Predictors of side branch occlusions just after coronary stenting. Korean J Med 2004;67:153–160.
29. Lee SW, Lee SW, Hong MK, et al. Bail-out stenting for left main coronary artery dissection during catheter-based procedure: acute and long-term results. Korean J Med 2004;66:571–575.
30. Rossini R, Capodanno D, Lettieri C, et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011;107:186–194.
31. Kaiser C, Galatius S, Erne P, et al. Drug-Eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010;363:2310–2319.